NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.73 +0.71 (+0.91%) GOLD FUTURES
2,389.70 +29.80 (+1.26%) DOW
39,843.09 +284.98 (+0.72%) Bitcoin GBP
51,672.76 +3,249.09 (+6.71%)
Codexis, Inc. (CDXS)
- GlobeNewswire
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic manufacturing milestone are being presented today in a Spotlight Presentation at the TIDES USA annual meeting taking place in Boston, MA, and virtually May 14 – 17, 2024. “The data presented today by Codexi
- Simply Wall St.
Codexis First Quarter 2024 Earnings: Beats Expectations
Codexis ( NASDAQ:CDXS ) First Quarter 2024 Results Key Financial Results Revenue: US$17.1m (up 32% from 1Q 2023). Net...
- Insider Monkey
Codexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Call Transcript May 2, 2024 Codexis, Inc. beats earnings expectations. Reported EPS is $-0.1647, expectations were $-0.17. Codexis, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Codexis’ First Quarter 2024 […]
